Tatva Chintan Pharma Chem Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹124Cr
- +49.4% YoY
- +6% QoQ
- Net profit
- ₹10Cr
- Turned profitable YoY
- +42.9% QoQ
- Margin
- 18%
- +11 pp YoY
- +3 pp QoQ
Guidance rank: #32 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters. Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand.
From Tatva Chintan Pharma Chem Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters.
- Agro Products: Anticipated 1.5x volume growth next financial year and another 1.5x growth in the following year. New agro intermediate with significant domestic demand expected to become a key product by 2027.
- Electrolyte Salts: Revenue projected to reach around INR15 crore in the current year, scaling up to 10% of total revenue by FY'27 with consistent volume growth and regular dispatches.
- Pharma and Agro Intermediates: Four agro and four pharma molecules expected to reach full potential in 2-3 years, collectively addressing a revenue potential of INR300-350 crore.
2 more points from Tatva Chintan Pharma Chem Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product.
- This new facility will help overcome production bottlenecks for newly commercialized agro and pharma intermediates.
- Additional capex rounds may be considered for scaling up certain agro products as demand grows.
- Plant scale changes are underway to enable delivery of commercial batches for semiconductor chemicals, targeted for Q4 of the current financial year.
2 more points from Tatva Chintan Pharma Chem Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is currently executing trial orders for individual solar plant energy shields in the energy storage system segment, indicating the beginning of commercialization.
- Small-scale commercial orders have been executed for hybrid batteries used in automotive applications, with positive customer feedback.
- Goods in transit for the PASC (Phase Transfer Catalysts) segment have increased from INR16-17 crores last quarter to INR26 crores this quarter, reflecting an active order pipeline.
- New large-scale agro intermediate commercialization has commenced, with production activities progressing as planned.
- Validation batches for new pharma and agro intermediates are underway, with commercialization expected from December 2025 to the second half of 2026.
- The semiconductor product pipeline includes products in piloting, with expected revenues ranging INR50-100 crores.
2 more points from Tatva Chintan Pharma Chem Ltd's call on order book
Create a free account to keep reading this call
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Tatva Chintan Pharma Chem Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 124 | 83 | +49.4% | 117 | +6% |
| Operating profit (EBITDA) | 22 | 6 | +266.7% | 17 | +29.4% |
| Operating margin | 18% | 7% | +11 pp | 15% | +3 pp |
| Profit before tax | 14 | -1 | — | 9 | +55.6% |
| Net profit (PAT) | 10 | -1 | — | 7 | +42.9% |
| EPS (₹) | 4.24 | -0.28 | — | 2.84 | +49.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Gujarat Alkalies (Q2 FY26)
2,136.64 Crores (Page 21). Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q2 FY26 investor presentation — and how it ranks against
- Dynemic Products (Q2 FY26)
Quarterly revenue for Q2 FY 25-26: ₹8,935 lakhs (Page 12, 10, 5) . Key investor presentation takeaways from Dynemic Products's Q2 FY26 investor presentation — a
- Platinum Industr (Q2 FY26)
Q2FY26 Revenue from Operations (Consolidated): INR 983.8 Mn, down 1% YoY from INR 996.4 Mn in Q2FY25. Key investor presentation takeaways from Platinum Industri
- IVP (Q2 FY26)
Revenue from Operations for Q2FY26: ₹146.95 crores . Key investor presentation takeaways from IVP's Q2 FY26 investor presentation — and how it ranks against sec
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Tatva Chintan Pharma Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q2 FY26 results?
SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters. Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
